1
Return

Phase 2 study of regorafenib in patients with progressive glioblastoma after failure of bevacizumab

delete2026-06-09
delete0
delete
OA
AI
A
Alyssa Lucas, MD
D
David Peereboom, MD FACP *
Y
Yasmeen Rauf, MD
H
Hong Li
J
Joshua Hanlon
M
Manmeet Ahluwalia, MD MBA FASCO
DOI：10.1093/noajnl/vdag144delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Treatment options in progressive glioblastoma (GBM) are limited, especially in patients who have experienced disease progression while receiving bevacizumab therapy. This phase 2 study was conducted to evaluate the efficacy and safety of regorafenib monotherapy in patients with GBM.

Journal

N
Neuro-Oncology Advances
IF:
4.1
Papers:
1.5K
Citations:
3.2K

Organization

C
cleveland clinic foundation
Scholars:
3.6W
Papers: 3.0W
Citations: 28
Cited Papers

Cited Papers

Citing Papers

Citing Papers